Clinical and genetic characterization of manifesting carriers of DMD mutations

Payam Soltanzadeh, Michael J. Friez, Diane Dunn, Andrew von Niederhausern, Olga L. Gurvich, Kathryn J. Swoboda, Jacinda B. Sampson, Alan Pestronk, Anne M. Connolly, Julaine M. Florence, Richard S. Finkel, Carsten G. Bönnemann, Livija Medne, Jerry R. Mendell, Katherine D. Mathews, Brenda L. Wong, Michael D. Sussman, Jonathan (Jon) Zonana, Karen Kovak, Sidney M. Gospe & 5 others Eduard Gappmaier, Laura E. Taylor, Michael T. Howard, Robert B. Weiss, Kevin M. Flanigan

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Manifesting carriers of DMD gene mutations may present diagnostic challenges, particularly in the absence of a family history of dystrophinopathy. We review the clinical and genetic features in 15 manifesting carriers identified among 860 subjects within the United Dystrophinopathy Project, a large clinical dystrophinopathy cohort whose members undergo comprehensive DMD mutation analysis. We defined manifesting carriers as females with significant weakness, excluding those with only myalgias/cramps. DNA extracted from peripheral blood was used to study X-chromosome inactivation patterns. Among these manifesting carriers, age at symptom onset ranged from 2 to 47. years. Seven had no family history and eight had male relatives with Duchenne muscular dystrophy (DMD). Clinical severity among the manifesting carriers varied from a DMD-like progression to a very mild Becker muscular dystrophy-like phenotype. Eight had exonic deletions or duplications and six had point mutations. One patient had two mutations (an exonic deletion and a splice site mutation), consistent with a heterozygous compound state. The X-chromosome inactivation pattern was skewed toward non-random in four out of seven informative deletions or duplications but was random in all cases with nonsense mutations. We present the results of DMD mutation analysis in this manifesting carrier cohort, including the first example of a presumably compound heterozygous DMD mutation. Our results demonstrate that improved molecular diagnostic methods facilitate the identification of DMD mutations in manifesting carriers, and confirm the heterogeneity of mutational mechanisms as well as the wide spectrum of phenotypes.

Original languageEnglish (US)
Pages (from-to)499-504
Number of pages6
JournalNeuromuscular Disorders
Volume20
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Duchenne Muscular Dystrophy
Mutation
X Chromosome Inactivation
Phenotype
Muscle Cramp
Molecular Pathology
Nonsense Codon
Sequence Deletion
Myalgia
Age of Onset
Point Mutation
DNA
Genes

Keywords

  • Becker muscular dystrophy
  • DMD
  • Duchenne muscular dystrophy
  • Dystrophin
  • Dystrophinopathy
  • Manifesting carriers
  • X-chromosome inactivation

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Cite this

Soltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L., Swoboda, K. J., ... Flanigan, K. M. (2010). Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscular Disorders, 20(8), 499-504. https://doi.org/10.1016/j.nmd.2010.05.010

Clinical and genetic characterization of manifesting carriers of DMD mutations. / Soltanzadeh, Payam; Friez, Michael J.; Dunn, Diane; von Niederhausern, Andrew; Gurvich, Olga L.; Swoboda, Kathryn J.; Sampson, Jacinda B.; Pestronk, Alan; Connolly, Anne M.; Florence, Julaine M.; Finkel, Richard S.; Bönnemann, Carsten G.; Medne, Livija; Mendell, Jerry R.; Mathews, Katherine D.; Wong, Brenda L.; Sussman, Michael D.; Zonana, Jonathan (Jon); Kovak, Karen; Gospe, Sidney M.; Gappmaier, Eduard; Taylor, Laura E.; Howard, Michael T.; Weiss, Robert B.; Flanigan, Kevin M.

In: Neuromuscular Disorders, Vol. 20, No. 8, 08.2010, p. 499-504.

Research output: Contribution to journalArticle

Soltanzadeh, P, Friez, MJ, Dunn, D, von Niederhausern, A, Gurvich, OL, Swoboda, KJ, Sampson, JB, Pestronk, A, Connolly, AM, Florence, JM, Finkel, RS, Bönnemann, CG, Medne, L, Mendell, JR, Mathews, KD, Wong, BL, Sussman, MD, Zonana, JJ, Kovak, K, Gospe, SM, Gappmaier, E, Taylor, LE, Howard, MT, Weiss, RB & Flanigan, KM 2010, 'Clinical and genetic characterization of manifesting carriers of DMD mutations', Neuromuscular Disorders, vol. 20, no. 8, pp. 499-504. https://doi.org/10.1016/j.nmd.2010.05.010
Soltanzadeh P, Friez MJ, Dunn D, von Niederhausern A, Gurvich OL, Swoboda KJ et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscular Disorders. 2010 Aug;20(8):499-504. https://doi.org/10.1016/j.nmd.2010.05.010
Soltanzadeh, Payam ; Friez, Michael J. ; Dunn, Diane ; von Niederhausern, Andrew ; Gurvich, Olga L. ; Swoboda, Kathryn J. ; Sampson, Jacinda B. ; Pestronk, Alan ; Connolly, Anne M. ; Florence, Julaine M. ; Finkel, Richard S. ; Bönnemann, Carsten G. ; Medne, Livija ; Mendell, Jerry R. ; Mathews, Katherine D. ; Wong, Brenda L. ; Sussman, Michael D. ; Zonana, Jonathan (Jon) ; Kovak, Karen ; Gospe, Sidney M. ; Gappmaier, Eduard ; Taylor, Laura E. ; Howard, Michael T. ; Weiss, Robert B. ; Flanigan, Kevin M. / Clinical and genetic characterization of manifesting carriers of DMD mutations. In: Neuromuscular Disorders. 2010 ; Vol. 20, No. 8. pp. 499-504.
@article{a290d1fb8f154785a84e562bb2625bcb,
title = "Clinical and genetic characterization of manifesting carriers of DMD mutations",
abstract = "Manifesting carriers of DMD gene mutations may present diagnostic challenges, particularly in the absence of a family history of dystrophinopathy. We review the clinical and genetic features in 15 manifesting carriers identified among 860 subjects within the United Dystrophinopathy Project, a large clinical dystrophinopathy cohort whose members undergo comprehensive DMD mutation analysis. We defined manifesting carriers as females with significant weakness, excluding those with only myalgias/cramps. DNA extracted from peripheral blood was used to study X-chromosome inactivation patterns. Among these manifesting carriers, age at symptom onset ranged from 2 to 47. years. Seven had no family history and eight had male relatives with Duchenne muscular dystrophy (DMD). Clinical severity among the manifesting carriers varied from a DMD-like progression to a very mild Becker muscular dystrophy-like phenotype. Eight had exonic deletions or duplications and six had point mutations. One patient had two mutations (an exonic deletion and a splice site mutation), consistent with a heterozygous compound state. The X-chromosome inactivation pattern was skewed toward non-random in four out of seven informative deletions or duplications but was random in all cases with nonsense mutations. We present the results of DMD mutation analysis in this manifesting carrier cohort, including the first example of a presumably compound heterozygous DMD mutation. Our results demonstrate that improved molecular diagnostic methods facilitate the identification of DMD mutations in manifesting carriers, and confirm the heterogeneity of mutational mechanisms as well as the wide spectrum of phenotypes.",
keywords = "Becker muscular dystrophy, DMD, Duchenne muscular dystrophy, Dystrophin, Dystrophinopathy, Manifesting carriers, X-chromosome inactivation",
author = "Payam Soltanzadeh and Friez, {Michael J.} and Diane Dunn and {von Niederhausern}, Andrew and Gurvich, {Olga L.} and Swoboda, {Kathryn J.} and Sampson, {Jacinda B.} and Alan Pestronk and Connolly, {Anne M.} and Florence, {Julaine M.} and Finkel, {Richard S.} and B{\"o}nnemann, {Carsten G.} and Livija Medne and Mendell, {Jerry R.} and Mathews, {Katherine D.} and Wong, {Brenda L.} and Sussman, {Michael D.} and Zonana, {Jonathan (Jon)} and Karen Kovak and Gospe, {Sidney M.} and Eduard Gappmaier and Taylor, {Laura E.} and Howard, {Michael T.} and Weiss, {Robert B.} and Flanigan, {Kevin M.}",
year = "2010",
month = "8",
doi = "10.1016/j.nmd.2010.05.010",
language = "English (US)",
volume = "20",
pages = "499--504",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Clinical and genetic characterization of manifesting carriers of DMD mutations

AU - Soltanzadeh, Payam

AU - Friez, Michael J.

AU - Dunn, Diane

AU - von Niederhausern, Andrew

AU - Gurvich, Olga L.

AU - Swoboda, Kathryn J.

AU - Sampson, Jacinda B.

AU - Pestronk, Alan

AU - Connolly, Anne M.

AU - Florence, Julaine M.

AU - Finkel, Richard S.

AU - Bönnemann, Carsten G.

AU - Medne, Livija

AU - Mendell, Jerry R.

AU - Mathews, Katherine D.

AU - Wong, Brenda L.

AU - Sussman, Michael D.

AU - Zonana, Jonathan (Jon)

AU - Kovak, Karen

AU - Gospe, Sidney M.

AU - Gappmaier, Eduard

AU - Taylor, Laura E.

AU - Howard, Michael T.

AU - Weiss, Robert B.

AU - Flanigan, Kevin M.

PY - 2010/8

Y1 - 2010/8

N2 - Manifesting carriers of DMD gene mutations may present diagnostic challenges, particularly in the absence of a family history of dystrophinopathy. We review the clinical and genetic features in 15 manifesting carriers identified among 860 subjects within the United Dystrophinopathy Project, a large clinical dystrophinopathy cohort whose members undergo comprehensive DMD mutation analysis. We defined manifesting carriers as females with significant weakness, excluding those with only myalgias/cramps. DNA extracted from peripheral blood was used to study X-chromosome inactivation patterns. Among these manifesting carriers, age at symptom onset ranged from 2 to 47. years. Seven had no family history and eight had male relatives with Duchenne muscular dystrophy (DMD). Clinical severity among the manifesting carriers varied from a DMD-like progression to a very mild Becker muscular dystrophy-like phenotype. Eight had exonic deletions or duplications and six had point mutations. One patient had two mutations (an exonic deletion and a splice site mutation), consistent with a heterozygous compound state. The X-chromosome inactivation pattern was skewed toward non-random in four out of seven informative deletions or duplications but was random in all cases with nonsense mutations. We present the results of DMD mutation analysis in this manifesting carrier cohort, including the first example of a presumably compound heterozygous DMD mutation. Our results demonstrate that improved molecular diagnostic methods facilitate the identification of DMD mutations in manifesting carriers, and confirm the heterogeneity of mutational mechanisms as well as the wide spectrum of phenotypes.

AB - Manifesting carriers of DMD gene mutations may present diagnostic challenges, particularly in the absence of a family history of dystrophinopathy. We review the clinical and genetic features in 15 manifesting carriers identified among 860 subjects within the United Dystrophinopathy Project, a large clinical dystrophinopathy cohort whose members undergo comprehensive DMD mutation analysis. We defined manifesting carriers as females with significant weakness, excluding those with only myalgias/cramps. DNA extracted from peripheral blood was used to study X-chromosome inactivation patterns. Among these manifesting carriers, age at symptom onset ranged from 2 to 47. years. Seven had no family history and eight had male relatives with Duchenne muscular dystrophy (DMD). Clinical severity among the manifesting carriers varied from a DMD-like progression to a very mild Becker muscular dystrophy-like phenotype. Eight had exonic deletions or duplications and six had point mutations. One patient had two mutations (an exonic deletion and a splice site mutation), consistent with a heterozygous compound state. The X-chromosome inactivation pattern was skewed toward non-random in four out of seven informative deletions or duplications but was random in all cases with nonsense mutations. We present the results of DMD mutation analysis in this manifesting carrier cohort, including the first example of a presumably compound heterozygous DMD mutation. Our results demonstrate that improved molecular diagnostic methods facilitate the identification of DMD mutations in manifesting carriers, and confirm the heterogeneity of mutational mechanisms as well as the wide spectrum of phenotypes.

KW - Becker muscular dystrophy

KW - DMD

KW - Duchenne muscular dystrophy

KW - Dystrophin

KW - Dystrophinopathy

KW - Manifesting carriers

KW - X-chromosome inactivation

UR - http://www.scopus.com/inward/record.url?scp=77955268106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955268106&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2010.05.010

DO - 10.1016/j.nmd.2010.05.010

M3 - Article

VL - 20

SP - 499

EP - 504

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 8

ER -